C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F19%3A00112475" target="_blank" >RIV/00216224:14110/19:00112475 - isvavai.cz</a>

Result on the web

<a href="http://dx.doi.org/10.1056/NEJMc1910394" target="_blank" >http://dx.doi.org/10.1056/NEJMc1910394</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1056/NEJMc1910394" target="_blank" >10.1056/NEJMc1910394</a>

Result language

angličtina

Original language name

C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia

Original language description

Savarirayan et al. (July 4 issue)1 report increased skeletal growth in patients with achondroplasia (a common type of dwarfism caused by activating mutations in the tyrosine kinase fibroblast growth factor receptor 3 gene FGFR3) who received vosoritide, a stable analogue of C-type natriuretic peptide. Their study is a breakthrough in treatment for achondroplasia, and it offers an intriguing possibility of broader clinical applications.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

10608 - Biochemistry and molecular biology

Project

—

Continuities

S - Specificky vyzkum na vysokych skolach<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2019

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

New England Journal of Medicine

ISSN

0028-4793

e-ISSN

1533-4406

Volume of the periodical

381

Issue of the periodical within the volume

13

Country of publishing house

GB - UNITED KINGDOM

Number of pages

1

Pages from-to

1291

UT code for WoS article

000489333500020

EID of the result in the Scopus database

2-s2.0-85072669028